Immunome Research

Immunome Research
Open Access

ISSN: 1745-7580

+44-77-2385-9429

Immunome Research : Citations & Metrics Report

Articles published in Immunome Research have been cited by esteemed scholars and scientists all around the world. Immunome Research has got h-index 15, which means every article in Immunome Research has got 15 average citations.

Following are the list of articles that have cited the articles published in Immunome Research.

  2024 2023 2022 2021 2020 2019 2018 2017

Total published articles

30 37 20 40 13 7 20 17

Conference proceedings

0 0 0 0 0 0 99 44

Citations received as per Google Scholar, other indexing platforms and portals

74 82 94 111 117 98 76 71
Journal total citations count 952
Journal impact factor 9.00
Journal 5 years impact factor 10.13
Journal cite score 13.75
Journal h-index 15
Journal h-index since 2019 13
Important citations (1540)

Bu r, deng x, cao y, jin j, mai b, meng k, liu x, chi jc, zhang y, qiu f. effect of different sample treatment methods on low endotoxin recovery phenomenon. journal of microbiological methods. 2021 jul 1;186:106241.

Gregoritza k, cai sk, siketanc m, woehr a, lebouc v, kishore rs, nicoulin v, bleher s, allmendinger a. metal-induced fatty acid particle formation resulting from hydrolytic polysorbate degradation. journal of pharmaceutical sciences. 2021 oct 1.

Nersesjan v, mcwilliam o, krarup lh, kondziella d. autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors: systematic review. neurology. 2021 may 5.

Tinker-kulberg r, dellinger al, brady te, robertson l, goddard mk, bowzer j, abood sk, kepley c, dellinger k. effects of diet on the biochemical properties of amebocyte lysates from limulus polyphemus in an aquaculture setting. frontiers in marine science. 2020;7:860.

Gerasymchuk m, cherkasova v, kovalchuk o, kovalchuk i. the role of micrornas in organismal and skin aging. international journal of molecular sciences. 2020 jan;21(15):5281.

Pavlick a, weber j. managing checkpoint inhibitor symptoms and toxicity for metastatic melanoma. cutaneous melanoma. 2020:1187-214.

Ufimtseva eg. role of mitochondria and antiapoptic protein bcl-2 in relationship of mycobacteria with host cells in granules of mice with latent tuberculosis infection. mechanisms of regulation of functions of eukaryotic cell organelles / mate. 2018: 139.

Wolf j, willscher e, loeffler-wirth h, schmidt m, flemming g, zurek m, uhlig hh, händel n, binder h. deciphering the transcriptomic heterogeneity of duodenal coeliac disease biopsies. international journal of molecular sciences. 2021 jan;22(5):2551.

Fan s, ren h, zhao l, yin j, feng g, wang j, guan h. neurological immune?related adverse events associated with immune checkpoint inhibitors: a review of the literature. asia?pacific journal of clinical oncology. 2020 dec;16(6):291-8.

Dunne mr, byrne g, chirdo fg, feighery c. coeliac disease pathogenesis: the uncertainties of a well-known immune mediated disorder. frontiers in immunology. 2020 jul 8;11:1374.

Ricardo goulart l, souza santos p, paula carneiro a, brasil santana b, c vallinoto a, goncalves araujo t. unraveling antibody display: systems biology and personalized medicine. current pharmaceutical design. 2016 dec 1;22(43):6560-76.

Strik h, keber u, hammoud wa, riera-knorrenschild j, carl b, dodel r, pagenstecher a, neubauer a. immune checkpoint inhibitor–associated cns autoimmune disorder (icicad) following nivolumab treatment: a new entity of drug-induced autoimmune encephalitis?. european journal of cancer. 2017 dec 1;87:205-8.

Richard k, weslow j, porcella sl, nanjappa s. a case report of steroid responsive nivolumab-induced encephalitis. cancer control. 2017 dec 21;24(5):1073274817729069.

Zurko j, mehta a. association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy. mayo clinic proceedings: innovations, quality & outcomes. 2018 mar 1;2(1):74-7.

Blackmon jt, viator t, conry rm. central nervous system toxicities of anti-cancer immune checkpoint blockade. journal of neurology & neuromedicine. 2016 jul 30;1(4).

Feng s, coward j, mccaffrey e, coucher j, kalokerinos p, o’byrne k. pembrolizumab-induced encephalopathy: a review of neurological toxicities with immune checkpoint inhibitors. journal of thoracic oncology. 2017 nov 1;12(11):1626-35.

Larkin j, chmielowski b, lao cd, hodi fs, sharfman w, weber j, suijkerbuijk kp, azevedo s, li h, reshef d, avila a. neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis. the oncologist. 2017 jun;22(6):709.

Wang h, lu h, zhang xm, goto ki, kobayashi e, yoshida y, adachi a, matsutani t, iwadate y, mine s, machida t. association of serum levels of antibodies against aldoa and fh4 with transient ischemic attack and cerebral infarction. bmc neurology. 2021 dec;21(1):1-3.

Williams tj, benavides dr, patrice ka, dalmau jo, de Ávila al, le dt, lipson ej, probasco jc, mowry em. association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. jama neurology. 2016 aug 1;73(8):928-33.

Antonia sj, lópez-martin ja, bendell j, ott pa, taylor m, eder jp, jäger d, pietanza mc, le dt, de braud f, morse ma. nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (checkmate 032): a multicentre, open-label, phase 1/2 trial. the lancet oncology. 2016 jul 1;17(7):883-95.

Top